Latest stories on CMND
Clearmind completes patient recruitment for AUD cohort of CMND-100 trial
The Fly61 · neutralproduct/pr
Clearmind Successfully Completes Patient Recruitment for the First Alcohol Use Disorder Cohort of its CMND-100 Phase I/IIa Clinical Trial
GlobeNewswire58 · neutralproduct/pr
Clearmind Medicine’s Charging Robotics launches robotaxi charging platform
The Fly58 · neutralproduct/pr
Clearmind: Charging Robotics Launches Next-Generation Automated EV-Charging Technology for Robotaxis and Autonomous Fleets
GlobeNewswire58 · neutralproduct/pr
Clearmind: Charging Robotics Launches Next-Generation Automated EV-Charging Technology for Robotaxis and Autonomous Fleets
Business Insider58 · neutralproduct/pr
Clearmind Medicine publishes patent application in Japan for treating dyskinesia
The Fly56 · neutralproduct/pr
Clearmind Announces Patent Publication in Japan Covering Treatment for Neurological Movement Disorder
StockTitan58 · neutralproduct/pr
Clearmind Medicine submits psychedelic therapy recommendations to FDA
The Fly56 · neutralgeneral
Clearmind (CMND) Pushes for At-Home-Friendly, Non-Hallucinogenic Psychedelic Pathways in FDA Submission
October 7, 2026
MarketChameleon63 · neutralproduct/pr
Clearmind Advances Dialogue with U.S. Federal Government on Psychedelic Therapies, Submitting Recommendations to FDA
Business Insider56 · neutralgeneral
Clearmind Medicine Inc trading halted, news pending
The Fly48 · neutralgeneral
SciSparc Spotlights Three Published U.S. Patent Applications Linking PEA With LSD, Ketamine, and Ibogaine
September 24, 2026
MarketChameleon58 · neutralproduct/pr
SciSparc spotlights three published U.S. patent applications pairing PEA with LSD, ketamine, and ibogaine
September 23, 2026
MarketChameleon58 · neutralproduct/pr
SciSparc expands U.S. IP portfolio in collaboration with Clearmind Medicine
The Fly63 · neutralproduct/pr
Clearmind Medicine announces publication in U.S. of 3 patent applications
The Fly59 · neutralproduct/pr
Clearmind Enhances U.S. IP Presence with Publication of Three Patent Applications Covering LSD, Ketamine and Ibogaine Combinations
GlobeNewswire63 · neutralproduct/pr
Clearmind Medicine Delivers Briefing to FDA Following Invitation to Historic Psychedelic Hearing in Washington, D.C.
GlobeNewswire58 · neutralgeneral
Clearmind Medicine Delivers Briefing to FDA Following Invitation to Historic Psychedelic Hearing in Washington, D.C.
StockTitan56 · neutralgeneral
Clearmind Medicine enrolls first patients with AUD in CMND-100 trial
The Fly58 · neutralproduct/pr
Clearmind Enrolls First Patients with Alcohol Use Disorder in CMND-100 Clinical Trial
GlobeNewswire56 · neutralproduct/pr
Clearmind Enrolls First Patients with Alcohol Use Disorder in CMND-100 Clinical Trial
Business Insider56 · neutralproduct/pr